Tech Company Inital Public Offerings
Metacrine IPO
Based in San Diego, Metacrine is now a public company.
Transaction Overview
Company Name
Announced On
9/16/2020
Transaction Type
IPO
Amount
$85,020,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $10.0 million to fund our planned MET409 Phase 2a combination clinical trial in NASH through completion;approximately $15.0 million to fund our planned MET642 Phase 2a monotherapy clinical trial in NASH through completion;approximately $5.0 million to fund a Phase 2a monotherapy clinical trial of either MET409 or MET642 in UC through initial partial enrollment;approximately $9.0 - $13.0 million to fund a Phase 2b monotherapy clinical trial of either MET409 or MET642 in NASH through initial partial enrollment; andthe remainder to fund any potential future clinical trials and preclinical programs, and for working capital and other general corporate purposes, including the additional costs associated with being a public company.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3985 Sorrento Valley Blvd. C
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Metacrine (Nasdaq: MTCR) is a biotech company founded in 2015 on technology licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Preston Klassen
Chief Financial Officer
Trisha Millican
Vice President
Nicholas Smith
VP - Operations
Eric Bischoff
Browse more venture capital transactions:
Prev: 9/16/2020: Volansi venture capital transaction
Next: 9/16/2020: Hungry Harvest venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs